Physician profile
Steven David
NPI 1902896723
$6,420.59
in general payments reported to CMS, 2019-2025
35 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $432 · 2021: $803 · 2022: $935 · 2023: $1,050 · 2024: $1,326 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,600.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,633.43 | 2019-2025 | Rinvoq, Creon, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $957.57 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $480.84 | 2019-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $416.82 | 2019-2024 | Dificid, Zinplava |
| Takeda Pharmaceuticals U.S.A., INC. | $399.32 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $363.40 | 2021-2024 | Zeposia |
| Pfizer INC. | $354.07 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $224.24 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $178.77 | 2019-2025 | |
| Madrigal Pharmaceuticals | $176.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $171.51 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $103.80 | 2019-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $103.36 | 2019-2023 | Linzess |
| Thd America, INC. | $95.14 | 2025 | |
| Phathom Pharmaceuticals, INC. | $94.22 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $60.82 | 2021-2025 | |
| Braintree Laboratories, INC. | $56.85 | 2019-2023 | Suflave |
| Laborie Medical Technologies Corp. | $51.75 | 2024 | |
| Lilly USA, LLC | $50.13 | 2024-2025 | Omvoh |
| Ucb, INC. | $42.68 | 2019-2020 | |
| Redhill Biopharma INC. | $42.25 | 2021-2023 | Talicia |
| Ethicon US, LLC | $38.62 | 2021 | |
| Genzyme Corporation | $38.11 | 2022-2024 | |
| Celltrion USA INC. | $37.39 | 2025 | Vegzelma |
| Novo Nordisk INC | $36.94 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $34.34 | 2024-2025 | Ayvakit |
| Qol Medical, LLC | $29.36 | 2022 | |
| Organon LLC | $28.86 | 2021 | |
| Capsovision, INC. | $22.80 | 2024 | Capsocam Plus |
| Exact Sciences Corporation | $20.79 | 2023 | Cologuard Collection Kit |
| Biocon Biologics INC | $19.79 | 2025 | Yesintek |
| Cumberland Pharmaceuticals, INC. | $17.91 | 2024 | Kristalose |
| Allergan, INC. | $13.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.93 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.